First study of clonal evolution in Maxillary Sinus Carcinoma

September 28, 2012

Knowing how tumors evolve can lead to new treatments that could help prevent cancer from recurring, according to a study published today by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.

TGen researchers tracked several years of tumor evolution in a 47-year-old male patient with maxillary sinus (MSC), a rare cancer of the sinus cavities beneath the cheeks that often requires surgical removal that is disfiguring. Fewer than half of MSC patients live more than 5 years after diagnosis.

"The ability to characterize clonal evolution of this and identify its Achilles' heel can significantly impact treatment, leading to more personalized medicine," according to the study published today in the journal .

Clonal evolution refers to the often-rapid genetic changes that occur in , which continually mutate and, thus, frequently resist anti-cancer drug compounds intended to destroy them.

"If we can understand the genomic basis of how this cancer evolves, perhaps we can find new treatments that could help improve the longevity and quality of life for patients," said Dr. Glen Weiss, Clinical Associate Professor at TGen, and Director of Thoracic Oncology at Virginia G. Piper Clinical Trials at Scottsdale Healthcare, a partnership with TGen. Dr. Weiss is one of the study's senior co-authors.

MSC represents nearly four of every five cases of paranasal sinus cancers, which grow rapidly and invade nearby tissues but also are usually slow to spread to distant sites. Patients usually die from a local of the tumor, even after .

"This is the first report to study the clonal population of MSC arising in longitudinal samples from the same patient," the study said. "One of the aims of this study was to closely follow and the clonally evolving for molecular profiling and accumulation of data for future use in development of personalized treatment."

The patient in the study received conventional treatment, which included surgical removal of his tumors, radiation therapy and chemotherapy, and participation in a clinical trial.

Over time, however, the cancer spread to his upper right lung, lower left lung, left kidney, brain and part of his intestine. He eventually was hospitalized, received hospice care and prior to passing away gave permission to have his cancer studied after death in a rapid autopsy research program.

"Because his cancer resumed growth despite several courses of systemic chemotherapy and radiation therapy, we speculated that acquired secondary genetic changes evolved with the evolution of resistance to these therapies," said Dr. Michael Barrett, Associate Professor in TGen's Clinical Translational Research Division, and the study's other senior co-author.

Analysis of his tumors following surgeries, biopsies and autopsy revealed several genetic aberrations, including multiple copies of a region on chromosome 4q, which includes the KIT gene. KIT is an oncogene, a gene with the potential to cause cancer, and is a potential treatment target.

The authors suggest the results provide a unique description of how the drug resistant cancer cells replicate and progress to metastatic MSC. Additional findings included the loss of the gene PKP4, which is associated with increased tumor size.

"These results show that molecular analyses of patient samples can add to the information about the tumor and help us in tracking back the progression of the disease," the authors concluded. "Identification of selected , and the biological processes they regulate arising in primary MSC tumors, will advance individualizing therapy and improve the outcome of patients with rare cancers."

"These kinds of cutting-edge studies are made possible through the collaboration of major research and clinical practices, such as the partnership between and Scottsdale Healthcare," said Dr. Mark Slater, Vice President of Research at Scottsdale Healthcare.

The authors remain particularly grateful to the patient and his family for their contribution to understanding more about this type of cancer and hope this dissemination of knowledge may help others.

Scottsdale Healthcare, Scottsdale Medical Imaging, and Sun Health Research Institute at Banner Healthcare contributed to this study, which was funded by the IBIS Foundation of Arizona and by the Scottsdale Healthcare Foundation.

Explore further: Study targets non-small cell lung cancer

More information: dx.plos.org/10.1371/journal.pone.0045614

Related Stories

Study targets non-small cell lung cancer

August 29, 2012
A Phase I/II, multi-center trial designed to test the safety and preliminary efficacy of a first in class cancer treatment opened worldwide today at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, ...

Whole genome sequencing of rare olfactory neuroblastoma

May 23, 2012
The Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have conducted whole genome sequencing (WGS) of a rare nasal tract cancer called olfactory neuroblastoma ...

FDA approves new skin cancer drug

February 1, 2012
A new skin cancer drug tested for the first time in the world five years ago at the Virginia G. Piper Cancer Center at Scottsdale Healthcare just received expedited approval by the U.S. Food and Drug Administration, a remarkable ...

TGen, Virginia G. Piper Cancer Center studying new breast cancer drug

July 20, 2011
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.